Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
Abstract Background We aimed to compare intra- and extracranial responses to immune checkpoint inhibitors (ICIs) in lung cancer with brain metastases (BM), and to explore tumor microenvironments of the brain and lungs focusing on the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-...
Main Authors: | Ryul Kim, Bhumsuk Keam, Sehui Kim, Miso Kim, Se Hyun Kim, Jin Wook Kim, Yu Jung Kim, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Jong Seok Lee, Dae Seog Heo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-5214-8 |
Similar Items
-
Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer
by: Eun Hee Jung, et al.
Published: (2021-03-01) -
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
by: Seong-Ho Kang, et al.
Published: (2019-01-01) -
MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function
by: Hyun Kyung Ahn, et al.
Published: (2019-09-01) -
Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
by: Juwon Lee, et al.
Published: (2021-07-01) -
Immune checkpoint blockade therapy for bladder cancer treatment
by: Jayoung Kim
Published: (2016-06-01)